Inclusion Criteria:

          -  Signed written informed consent obtained prior to study procedures

          -  Histologically confirmed HCC with serum AFP >200ng/ml at time of screening and
             following most current line of therapy OR radiographic diagnosis of HCC with serum AFP
             >400ng/ml at time of screening and following most current line of therapy..

          -  Metastatic or locally advanced, unresectable HCC

          -  Must have failed or not tolerated, at least one line of systemic therapy for advanced
             HCC

          -  Molecular Human Leukocyte Antigen ("HLA") class I allele typing confirms participant
             carries at least one HLA-A2 allele

          -  Life expectancy of at least 4 months

          -  Karnofsky Performance Scale greater than or equal to 70

          -  At least 1 measurable lesion on imaging by RECIST

          -  Child-Pugh A or B7

          -  Absolute neutrophil count greater than or equal to 1,500/mm^3

          -  Platelet count greater than or equal to 30,000/mm^3

        Exclusion Criteria:

          -  Clinically significant cardiac disease

          -  Clinically significant pre-existing illness or active infection

          -  Clinically significant Central Nervous System (CNS) or neural dysfunction

          -  Active autoimmune disease requiring therapy

          -  Active malignancy other than HCC unless expected survival is greater than or equal to
             three years without any treatment (exception: hormone/androgen-depravation therapy)
             and without any organ involvement

          -  History of organ transplant

          -  Compromised circulation in portal vein, hepatic vein, or vena cava due to obstruction

          -  Advanced HCC involving greater than one-third of the liver